Targeting non-Hodgkin lymphoma with blinatumomab

Expert Opinion on Biological Therapy
Sheilagh Sanders, Douglas A Stewart

Abstract

Management of patients with relapsed or refractory non-Hodgkin lymphoma (NHL) remains challenging, and novel effective agents are eagerly awaited. Blinatumomab is a bispecific T-cell engager, targeting CD19. While blinatumomab's primary clinical use has been in B-cell acute lymphoblastic leukemia (B-ALL), there are increasing data for its use in B-lineage lymphomas. Areas covered: The aim of this review is to highlight the clinical data for blinatumomab use in NHL. Herein, the authors provide an overview of blinatumomab, its mechanism of action, its proven efficacy against B-ALL, and its phase I-II data assessing its use in NHL Expert opinion: Blinatumomab has modest activity in phase I-II trials in NHL, and may represent a means of bridging patients with relapsed disease to hematopoietic stem cell transplant. More widespread use is currently hampered by lack of phase III data, multiple competing agents, an onerous administration schedule and significant side effect profile. Further studies are eagerly awaited assessing its use in combination with other immunotherapy strategies.

References

May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FeugierB Coiffier
Jan 23, 2009·Immunobiology·Cornelia HaasPatrick A Baeuerle
May 21, 2009·Leukemia & Lymphoma·Dirk NagorsenGerhard Zugmaier
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz
Sep 4, 2012·Pharmacology & Therapeutics·Dirk NagorsenRalf Bargou
Nov 27, 2015·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Matthew J Newman, Dina J Benani
Dec 20, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Megan Brafford May, Ashley Glode
Feb 18, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria-Elisabeth GoebelerRalf C Bargou
Mar 2, 2017·The New England Journal of Medicine·Hagop KantarjianMax S Topp

❮ Previous
Next ❯

Citations

Jan 10, 2018·Frontiers in Immunology·Isabel Corraliza-GorjónLeonor Kremer
Nov 1, 2018·Annual Review of Medicine·Raphael A Clynes, John R Desjarlais
Jun 1, 2020·Journal for Immunotherapy of Cancer·John P LynesEdjah K Nduom
Dec 21, 2018·Frontiers in Oncology·John LynesEdjah Nduom

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Expert Opinion on Investigational Drugs
Eunhye Oak, Nancy L Bartlett
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Matthew J Newman, Dina J Benani
© 2022 Meta ULC. All rights reserved